Trial Profile
An Open-label Trial Investigating the Association Between Nocturia and Sleep During 12 Weeks of Treatment with Desmopressin Orally Disintegrating Tablet (ODT) for Nocturia due to Nocturnal Polyuria in Adults
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 03 Oct 2018
Price :
$35
*
At a glance
- Drugs Desmopressin (Primary)
- Indications Nocturia
- Focus Therapeutic Use
- Acronyms AWAKEN
- Sponsors Ferring Pharmaceuticals
- 28 Sep 2018 This trial was completed in Netherlands (end date: 2018-07-13), according to European Clinical Trials Database.
- 22 Aug 2018 This trial was completed in Hungary (end date: 2018-07-13), according to European Clinical Trials Database.
- 17 Nov 2017 New trial record